Physician profile

Mitchell E Temple

New Orleans, LA

NPI 1952983769

$1,900.40

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$1,000.00
Food and Beverage$469.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $1,035.12 2023-2024 Davinci Xi
Davol INC. $157.00 2022
W. L. Gore & Associates, INC. $152.01 2024 Gore Viabahn Vbx Balloon Expandable Endo, Gore Propaten Vascular Graft
Penumbra, INC. $145.97 2024 Penumbra System
Medtronic, INC. $145.75 2021
Ethicon US, LLC $136.28 2024 Vistaseal, Enseal X1
Baxter Healthcare $116.48 2022
Allergan, INC. $11.79 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mitchell E Temple

$1,900.40

in general payments reported 2019-2025

Years
2021-2024
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/8906978/mitchell-e-temple

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.